Literature DB >> 32402580

Mortality and Implant Survival With Simultaneous and Staged Bilateral Total Hip Arthroplasty: Experience From the Australian Orthopedic Association National Joint Replacement Registry.

Lorenzo Calabro1, Mostyn Yong2, Sarah L Whitehouse2, Alesha Hatton3, Richard de Steiger4, Ross W Crawford2.   

Abstract

BACKGROUND: Total hip arthroplasty (THA) is an effective procedure for relieving pain and restoring function in osteoarthritis. A significant proportion of patients have severe disease bilaterally. Consensus regarding safety and selection of patients for simultaneous bilateral THA or the optimal timing for staged THA has not been reached. The aim of this study is to compare rates, causes of revision, and 30-day mortality between simultaneous and staged bilateral THA using data from the Australian Orthopedic National Joint Replacement Registry.
METHODS: Data for 12,359 bilateral THA procedures were collected from September, 1999 to December, 2017. Rates and causes of revision and 30-day mortality were obtained for simultaneous bilateral and staged procedures with intervals of 1 day-6 weeks, 6 weeks-3 months, and 3 months-6 months. Yearly cumulative percent revision or cumulative percent survival with 95% confidence intervals calculated by the Kaplan-Meier method, and adjusted hazard ratios were used for comparisons.
RESULTS: Thirty-day mortality is lower in patients who have bilateral procedures within 6 months, regardless of timing, than those who have unilateral procedures (0.06% vs 0.18%). Staged bilateral THA had a significantly lower mortality than simultaneous bilateral THA (odds ratio 0.175, 95% confidence interval = 0.04-0.78, P = .022). When separate time intervals were compared, no significant differences were seen. Bilateral 6 week-3 months has a higher rate of revision from 1.5 years-2years compared with same day bilaterals (hazard ratio = 2.39, 95% confidence interval = 1.12, 5.09, P = .024). There were no other significant differences in the rate of revision between groups. The most common reasons for revision were fracture, loosening, and infection. Simultaneous bilateral procedures have a significantly higher rate of revision for fracture compared with staging 3-6 months (hazard ratio = 1.96 [1.27, 3.03], P = .002).
CONCLUSION: This study demonstrates that bilateral THA has a low mortality rate regardless of time interval between procedures. Simultaneous and staged bilateral THA have similar rates of revision.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  arthroplasty; bilateral; hip replacement; mortality; registry; revision; survivorship

Mesh:

Year:  2020        PMID: 32402580     DOI: 10.1016/j.arth.2020.04.027

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  4 in total

1.  Peri-operative Morbidity Associated with Bilateral Hip Arthroplasty for Inflammatory Arthritis: Results from a Consecutive Series of 168 Hips.

Authors:  Rahul George; V J Chandy; A I Christudoss; T D Hariharan; A ArunShankar; B Antonisamy; A T Oommen; Pradeep Mathew Poonnoose
Journal:  Indian J Orthop       Date:  2021-08-09       Impact factor: 1.033

2.  Incidence and risk factors for blood transfusion in simultaneous bilateral total hip arthroplasty.

Authors:  Xing Wang; Qiang Huang; Fuxing Pei
Journal:  Jt Dis Relat Surg       Date:  2021-11-19

3.  Conversion of failed proximal femoral nail antirotation to uncemented or cemented femoral component fixation: a multicentre retrospective study with a median 10-year follow-up.

Authors:  Wenbo Shi; Yaodong Zhang; Yangkai Xu; Xianshang Zeng; Hongjing Fu; Weiguang Yu
Journal:  BMC Musculoskelet Disord       Date:  2022-04-21       Impact factor: 2.562

4.  Simultaneous versus staged bilateral total hip arthroplasty: a systematic review and meta-analysis.

Authors:  Akam Ramezani; Amirhossein Ghaseminejad Raeini; Amirmohammad Sharafi; Mehrdad Sheikhvatan; Seyed Mohammad Javad Mortazavi; Seyyed Hossein Shafiei
Journal:  J Orthop Surg Res       Date:  2022-08-13       Impact factor: 2.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.